CMS and FDA Launch RAPID Initiative to Expedite Medicare Coverage for Breakthrough Devices
The Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) have initiated a new program to expedite Medicare coverage for specific breakthrough medical devices. Named the Regulatory Alignment for Predictable and Immediate Device (RAPID) initiative, this effort aims to streamline cooperation among CMS, FDA, and manufacturers during the review process for Class II and Class III breakthrough devices.
The RAPID approach seeks to drastically cut the time required for Medicare coverage approval, potentially enabling national coverage and payment to begin within two months after a device receives market authorization. This marks a significant improvement over the previous timeline, which often extended beyond a year.
FDA Commissioner Marty Makary emphasized the initiative's intent to provide swift access to critical medical treatments while minimizing procedural delays. The Advanced Medical Technology Association (AdvaMed) praised this progress, underscoring the importance of effective implementation to fully realize its benefits.
The FDA’s breakthrough device program is crucial for accelerating the evaluation and authorization of devices that present significant advancements in the treatment or diagnosis of severe conditions. However, industry stakeholders have raised concerns regarding delays in securing Medicare coverage post-FDA approval. A survey by the Stanford Byers Center for Biodesign and the Duke-Margolis Center for Health Policy indicated an average five-year wait from FDA authorization to national Medicare and commercial insurance coverage.
To tackle this delay, CMS proposes the Transitional Coverage for Emerging Technologies (TCET) pathway, commencing in 2024, to annually evaluate a limited number of breakthrough technologies for Medicare coverage. The RAPID pathway is anticipated to enhance this process through earlier collaboration among CMS, FDA, and manufacturers, aiming to streamline regulatory compliance requirements.
Approximately 40 devices are currently eligible for the RAPID pathway, with another 20 potentially qualifying, a CMS official noted. This structure facilitates early engagement with device manufacturers and ensures pivotal trial designs that meet both FDA requirements and Medicare coverage criteria.
Eligibility for RAPID requires breakthrough devices addressing specific unmet clinical needs for Medicare beneficiaries. Devices must also include investigational device exemption studies encompassing Medicare patients and agreed-upon clinical outcomes. Under RAPID, CMS will issue a proposed national coverage determination (NCD) simultaneously with FDA marketing authorization, followed by a 30-day public comment period. CMS Administrator Dr. Mehmet Oz highlighted the collaborative efforts to expedite access to innovative health technologies for beneficiaries.
The TCET pathway will be temporarily paused as CMS allocates resources to the RAPID initiative. A procedural notice for RAPID will be published in the Federal Register, opening a 60-day public comment window. CMS will address these comments in its final notice, affirming its commitment to advancing the provider-payer landscape.